Sodium/glucose cotransporter 2 (SGLT2) inhibitors improve cardiac function by reducing JunD expression in human diabetic hearts.
Sign Up to like & getrecommendations! Published in 2021 at "Metabolism: clinical and experimental"
DOI: 10.1016/j.metabol.2021.154936
Abstract: BACKGROUND The pathogenesis of experimental diabetic cardiomyopathy may involve the activator protein 1 (AP-1) member, JunD. Using non-diabetic heart transplant (HTX) in recipients with diabetes, we examined the effects of the diabetic milieu (hyperglycemia and… read more here.
Keywords: htx recipients; jund expression; jund; recipients diabetes ... See more keywords